• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors

    6/9/25 10:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BSGM alert in real time by email

    Los Angeles, CA & Vancouver, BC, June 09, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Trevor Bacon and Kellan Grenier, co-founders of Parcl, as Strategic Advisors. Together, they bring deep expertise at the intersection of decentralized finance, synthetic asset creation, and real-world asset tokenization.

    Parcl is a leading blockchain-native platform that enables users to gain exposure to real estate markets through synthetic, perpetual trading. Built on Solana, the platform offers users the ability to speculate on real estate price movements across major cities without owning physical properties. Under Trevor and Kellan's leadership, Parcl has become one of the most advanced protocols focused on bridging real estate and decentralized finance.

    Trevor Bacon is the CEO and Co-Founder of Parcl. Before launching the company, he spent over a decade in finance, including roles at Barclays and serving as a portfolio manager at several hedge funds where he led investments in technology, payments, and internet companies.

    Kellan Grenier, Co-Founder and COO of Parcl, brings extensive experience as a long/short equity analyst in the TMT sector and has been deeply involved in blockchain technology for over five years. His focus at Parcl spans strategic partnerships, tokenomics, and platform expansion.

    "Trevor and Kellan are true innovators in the space," said Henry McPhie, CEO of BioSig and Co-Founder of Streamex. "Their experience building one of the most forward-thinking decentralized trading platforms makes them an ideal fit for BioSig and Streamex's mission. Their insights will be instrumental as we scale our infrastructure for tokenizing and trading real-world assets, particularly in illiquid and fragmented markets."

    Trevor Bacon commented, "We're excited to advise BioSig and Streamex as it pioneers a new model for commodity markets. The tokenization of real-world assets will transform how institutions and individuals access and invest in the physical world."

    Kellan Grenier added, "BioSig and Streamex's approach aligns strongly with our belief in programmable financial assets and blockchain-based access to previously inaccessible asset classes. We're thrilled to support their vision."

    BioSig & Streamex's Advisory Board

    Trevor Bacon and Kellan Grenier join a distinguished group of strategic advisors at BioSig and Streamex, each bringing world-class experience to the company's mission of transforming global commodity markets through tokenization. The advisory team now includes:

    • Frank Giustra – Strategic Investor and Advisor on Commodities
      • Founder of Wheaton Precious Metals ($37B)
      • Founder of GoldCorp (Acquired by Newmont for $57B)
      • Founder of LionsGate Films ($2B)
    • Sean Roosen – Strategic Advisor on Mining and Asset Strategy
      • Founder, Executive Chairman, and CEO of Osisko Development Corp.
      • Founder & Former CEO of Osisko Mining (Acquired by Gold Fields for $2.2B)
      • Founder & Former CEO of Osisko Gold Royalties ($6.9B)
    • Mathew August – Strategic Advisor on US Capital Markets
      • Executive Chairman of Atlas Capital Partners
      • Active venture capitalist in Defense Tech, FinTech, and Aerospace
    • Trevor Bacon – Strategic Advisor on DeFi Infrastructure
      • CEO and Co-Founder of Parcl
      • Former Portfolio Manager and Barclays VP
    • Kellan Grenier – Strategic Advisor on Tokenized Asset Strategy and Web3 Integration
      • COO and Co-Founder of Parcl
      • Former Investment Analyst and blockchain strategist

    About BioSig Technologies

    BioSig Technologies, Inc. is an innovative medical technology company dedicated to redefining cardiac care through advanced signal processing and digital solutions. Its flagship PURE EP™ Platform combines proprietary hardware and software to capture ultra‑high–fidelity intracardiac signals, empowering electrophysiologists with unprecedented clarity during arrhythmia diagnosis and treatment. Designed to elevate standards in electrophysiology, the system is FDA 510(k) cleared and delivers real-time, noise-free electrogram visualization—enhancing safety, efficiency, and patient outcomes. Partnering closely with leading institutions like Mayo Clinic and distinguished engineering firms, BioSig is advancing next-generation healthcare tools that strive to save time, reduce costs, and improve lives.

    About Streamex  

    Streamex is a real-world asset (RWA) tokenization company focused in the commodities space. With the goal to bring commodity markets on chain, Streamex has developed primary issuance and exchange infrastructure that will revolutionize commodity finance. Streamex is led by a group of highly successful and seasoned executives from financial, commodities and blockchain industries.

    Streamex believes the future of finance lies in tokenization, innovative investment strategies, and decentralized markets. By merging advanced financial technologies with blockchain transparency, Streamex has created infrastructure and solutions that enhance liquidity, accessibility, and efficiency. Streamex's goal is to bridge the gap between traditional finance and the digital economy, unlocking new opportunities for investors and institutions worldwide. 

    Streamex is a wholly owned subsidiary of BioSig Technologies, Inc., a medical device technology company with an advanced digital signal processing technology platform, the PURE EP™ Platform, that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias.

    Forward Looking statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.   Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control.   It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether  we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the acquisition will be obtained and whether we will be able to maintain compliance with Nasdaq's listing criteria in connection with the acquisition and otherwise.  For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled "Risk Factors" in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law. 



    Todd Adler
    BioSig Technologies, Inc.
    Investor Relations
    12424 Wilshire Blvd Ste 745
    Los Angeles, CA 90025
    [email protected]
    203–409–5444, x104
    Henry McPhie
    CEO of BioSig, Co-Founder of Streamex
    [email protected]
    https://www.streamex.com/
    https://x.com/streamex

    Primary Logo

    Get the next $BSGM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BSGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioSig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering

    Los Angeles, CA, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), a gold tokenization infrastructure company, today announced the closing of its previously announced underwritten public offering, including a group of technology and mining thought leaders. The offering consisted of 3,852,149 shares of common stock at a public offering price of $3.90 per share with no pre-funded warrants. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses were approximately $15,023,381. The Company inte

    8/15/25 4:50:14 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering

    Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offerin

    8/13/25 11:10:13 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. Announces Proposed Public Offering

    Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ("BioSig" or the "Company") which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM) today announced its intention to offer shares of common stock (or pre-funded warrants in lieu thereof) through an underwritten public offering. All of the shares of common stock (or pre-funded warrants in lieu thereof) are being offered by the Company. The completion of the offering remains subject to market conditions, with no assurance regarding its timing, size, or terms. The Company intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, fo

    8/13/25 5:16:15 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on BioSig Technologies with a new price target

    The Benchmark Company initiated coverage of BioSig Technologies with a rating of Buy and set a new price target of $42.00

    2/8/21 7:32:50 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Williams Mitchell Young claimed ownership of 1,000,000 units of Restricted Common Stock (SEC Form 3)

    3 - BioSig Technologies, Inc. (0001530766) (Issuer)

    6/9/25 6:31:07 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Mcphie Karl Henry Michael

    3 - BioSig Technologies, Inc. (0001530766) (Issuer)

    6/9/25 6:29:42 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Lekstrom Morgan Lee

    3 - BioSig Technologies, Inc. (0001530766) (Issuer)

    6/9/25 6:27:01 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    SEC Filings

    View All

    BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events

    8-K - BioSig Technologies, Inc. (0001530766) (Filer)

    8/15/25 5:15:46 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by BioSig Technologies Inc.

    10-Q - BioSig Technologies, Inc. (0001530766) (Filer)

    8/15/25 4:53:03 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFR14A filed by BioSig Technologies Inc.

    DEFR14A - BioSig Technologies, Inc. (0001530766) (Filer)

    8/15/25 4:15:15 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Leadership Updates

    Live Leadership Updates

    View All

    BioSig & Streamex Appoint Defi Expert and Visionary, Russell Starr as Strategic Advisor

    BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), is pleased to announce the appointment of Russell Starr as Strategic Advisor to Streamex. Mr. Starr brings decades of experience in capital markets, business development, and transformative deal-making across, defi, traditional finance and emerging sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711280588/en/ A former executive on Bay Street and respected entrepreneur and financier, Mr. Starr has built a reputation for navigating high-stakes financial transactions and guiding comp

    7/11/25 9:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors

    Los Angeles, CA & Vancouver, BC, June 09, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Trevor Bacon and Kellan Grenier, co-founders of Parcl, as Strategic Advisors. Together, they bring deep expertise at the intersection of decentralized finance, synthetic asset creation, and real-world asset tokenization. Parcl is a leading blockchain-native platform that enables users to gain exposure to real estate markets through synthetic, perpetual trading. Built on Solana, the platform offers users the ability to speculate on

    6/9/25 10:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor

    Los Angeles, CA and Vancouver, BC, June 04, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Sean Roosen as Strategic Advisor to Streamex. Mr. Roosen, a globally recognized mining entrepreneur and financier, brings over three decades of experience in building and scaling multibillion-dollar resource ventures. Mr. Roosen is the Founder, Executive Chairman, and Chief Executive Officer of Osisko Development Corp., a premier North American gold development company. He is also the founder and former Executive Chairman and CE

    6/4/25 8:25:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Financials

    Live finance-specific insights

    View All

    BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

    Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module. Built around three highly differentiating features, PURE EP™ Software Version 6 with ACCUVIZ™ Module introduces the proprietary High Frequency Algorithm (HFA), a novel feature that identifies the key frequency components of cardiac data that can be difficult to identify within the traditional waveform presentation. O

    9/22/22 9:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig to Host Conference Call on December 21, 2021

    Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET. Conference Call DetailsDate: Tuesday, December 21, 2021Time: 2:00 PM Eastern Time (ET)Dial-in number for US callers (toll-free): 877-407-8293Dial-in number for U.S. and international callers (toll): +1 201-689-8349 To join the conference call online, please click here: BioSig Webcast A

    12/13/21 8:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

    SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

    11/14/24 3:58:00 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by BioSig Technologies Inc.

    SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)

    2/14/24 3:31:45 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by BioSig Technologies, Inc. (Amendment)

    SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

    7/12/21 8:29:21 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care